Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Next-Generation DNA Sequencing Clear all
Terminated Not applicable Interventional

Treatment of Multifocal Lung Adenocarcinoma

NCT01946100
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma Non-small-cell Lung, Adenocarcinoma
Interventions
Multifocal Lung Adenocarcinoma
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 17, 2026, 8:55 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pre-malignant States to Hematologic Malignancies in Firefighters

NCT06870760
View directory record Official record
Conditions
Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, Non Hodgkin Lymphoma, Leukemia, Multiple Myeloma, Plasma Cell Disorder
Interventions
Monoclonal Gammopathy, Complete Blood Count with differential (CBC w/ diff), Clonal hematopoiesis (CHIP)
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Neural Correlates of Hypoalgesia Driven by Observation

NCT03897998
View directory record Official record
Conditions
Pain, Virtual Reality, Placebo
Interventions
Naloxone, Saline
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Recruiting No phase listed Observational

Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer

NCT07673016
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma (UC), Hematuria, Upper Tract Urothelial Cancer
Interventions
Not listed
Lead sponsor
Convergent Genomics, Inc.
Network
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
21
States / cities
Oceanside, California • San Diego, California • San Jose, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Not applicable Interventional Results available

Effects of Sensory Flicker and Electrical Flicker Stimulation

NCT04188834
View directory record Official record
Conditions
Brain Diseases
Interventions
Customized version of DAVID device, Blackrock CereStim
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 17, 2026, 8:55 AM EDT
Not listed Phase 2 Interventional

Comparison of Frozen-thawed Embryo Transfers and Fresh Embryo Transfers With Whole Chromosome Analysis Using Next Generation Sequencing

NCT02000349
View directory record Official record
Conditions
Infertility
Interventions
PGD
Other
Lead sponsor
Reprogenetics
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 17, 2026, 8:55 AM EDT
Recruiting Phase 2 Interventional

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

NCT06954805
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell
Interventions
Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq
Drug · Device
Lead sponsor
Jennifer Amengual
Other
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 3 Interventional

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

NCT06075095
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
19
States / cities
Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 17, 2026, 8:55 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)

NCT07805044
View directory record Official record
Conditions
PHYSIOLOGICAL PHENOMENA, Homeostasis, Physical Functional Performance, Cardiorespiratory Fitness, Cardiometabolic Risk Factors, Mobility Limitation
Interventions
Standardized Physiologic Resilience Challenge, Multimodal Whole-Body Physiologic Monitoring, Research-Only Whole-Body Digital Twin Analysis
Procedure · Other
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2041
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Recruiting No phase listed Observational

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

NCT02610413
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2100
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Completed No phase listed Observational

Genetic Study of Familial Acute Lymphoblastic Leukemia

NCT03067584
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 17, 2026, 8:55 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer

NCT07374796
View directory record Official record
Conditions
Breast Cancer (Locally Advanced or Metastatic), Healthy Volunteers (HV), Unhealthy Volunteers, Breast Cancer Screening
Interventions
Epigenetic Assay
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2033
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epigenetics of Muscle Insulin Resistance

NCT03259984
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 17, 2026, 8:55 AM EDT
Not listed Not applicable Interventional

Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms

NCT05276466
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Polymerase Chain Reaction and Next-Generation DNA Sequencing
Diagnostic Test
Lead sponsor
MicroGenDX
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 17, 2026, 8:55 AM EDT
Completed No phase listed Observational

Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors

NCT01987726
View directory record Official record
Conditions
Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Daily Disposable Toric Soft Lenses Manufactured With an Alternative Hydration Process

NCT06967129
View directory record Official record
Conditions
Astigmatism
Interventions
Investigational daily disposable, soft, toric lenses manufactured on 4th Generation Technology (4GT) lines with extended mini-stack hydration using propylene glycol (PG) as the hydration solvent., ACUVUE® Oasys 1-Day for Astigmatism (AO1DfA) soft contact lenses manufactured on 3rd Generation Technology (3GT) legacy lines using isopropyl alcohol (IPA) as the hydration solvent.
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
20
States / cities
Mission Viejo, California • San Diego, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Terminated Not applicable Interventional

Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment

NCT02297087
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Standard of care based on target(s) identified via GWS.
Genetic
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 17, 2026, 8:55 AM EDT
Completed No phase listed Observational

Do Patients With Early Post Operative Recurrence of Pelvic Organ Prolapse Have a Genetic Predisposition?

NCT01614587
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Not listed
Lead sponsor
Atlantic Health System
Other
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 17, 2026, 8:55 AM EDT
Recruiting Not applicable Interventional

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT07067138
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
Interventions
Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT), TruSight(R) Oncology 500, TruSeq Matched Tumor Normal Whole Exome Sequencing Assay
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Not listed No phase listed Observational

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

NCT03724097
View directory record Official record
Conditions
Cancer
Interventions
RNA sequencing, Transcriptome analysis, target drug with the score above 0,1, target drug with the score equal or below 0,1, non-target drug, palliative care
Other · Drug
Lead sponsor
OmicsWay Corp.
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Walnut, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 17, 2026, 8:55 AM EDT
Active, not recruiting Not applicable Interventional

Quantitative Ultrasound (RS85 and R20) for Liver Fat Quantification in MASLD Using MRI-PDFF as Reference

NCT07192159
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
Interventions
Quantitative ultrasound (DeepUSFF)
Device
Lead sponsor
Seoul National University Hospital
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Implementation of Carrier Status Using Next Generation Sequencing

NCT01902901
View directory record Official record
Conditions
Genetic Disorders
Interventions
Whole Genome Sequencing, Carrier status testing
Genetic
Lead sponsor
Kaiser Permanente
Other
Eligibility
21 Years to 50 Years
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 17, 2026, 8:55 AM EDT
Not listed No phase listed Observational

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

NCT03521245
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
RNA sequencing, Transcriptome analysis, Trastuzumab, Chemotherapy
Other · Drug
Lead sponsor
OmicsWay Corp.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Timeline
2017 – 2022
U.S. locations
1
States / cities
Walnut, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 17, 2026, 8:55 AM EDT